These MAO-B inhibitors, which in contrast to drugs that acted on MAO-A did not potentiate the effects of tyramine, e.g. from food, had reasonable anti-Parkinson properties when given as monotherapy but could also prolong and increase the effects of L-DOPA when given in combination. The gene discussed is MAOB; the disease is Parkinson disease.